Lv1
70 积分 2025-07-21 加入
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
22天前
已完结
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
28天前
已完结
Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases
1个月前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
1个月前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
2个月前
已完结
Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden
2个月前
已完结
Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough
2个月前
已完结
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health A Systematic Review and Meta-Analysis
2个月前
已完结
Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study
2个月前
已完结
Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023
2个月前
已完结
皖公网安备34019202002308
